SVF Vaccines has entered into a research collaboration with Orexo AB to explore powder-based drug delivery technology for stabilizing mRNA vaccines. The partnership will assess whether Orexo’s AmorphOX technology can develop stable, spray-dried formulations of mRNA vaccines encapsulated in lipid nanoparticles (LNPs). The initial program will focus on determining if the drying process can preserve the structural properties of the nanoparticles and maintain mRNA functionality.
The collaboration combines SVF Vaccines’ experience in vaccine development with Orexo’s expertise in powder-based drug delivery. The aim is to address challenges in mRNA vaccine development, particularly maintaining the stability of the genetic material and its lipid nanoparticle carrier during storage and transportation.
Converting LNP-mRNA vaccines into stable powder formulations could enhance storage and distribution, potentially allowing for alternative administration methods, such as needle-free intranasal delivery. Viktor Drvota, CEO of KDventures, stated that the agreement represents a step in advancing SVF Vaccines’ vaccine technologies through partnerships.
Source: drug-dev.com · Image: InfluenzaA Virus (H3N2) by NIH Image Gallery, Public domain, via Wikimedia Commons
Get started today with Solo access →
